RE: Gap 2008Hey Josh,
Go to Sedar.com and look at the news release dated April 17th 2008. This is the reason for the spike.
Coles notes version of that release......
--> Statistically significant (Stat Sig) effectiveness of its lead cancer drug, PhG-alpha-1 (GAP-107B8), in treating human breast and colon cancer.
Breast cancer metastatic model
--> In the group of 5 mice receiving PhG-alpha-1 at the dose of 1 mg/kg body weight, 4 of 5 (80%)when euthanized at the end of the trial period were observed to be tumour-free on post mortem
examination, with no effect on other organs. The remaining mouse had developed a single small,
friable (easily broken down) tumour. In the two control groups (saline and chemotherapy alone), 9
of 10 (90%) developed tumours, with only one surviving to the end of the trial and with ancillary
organ damage to some degree. For all other treatment groups, 22 of 25 (88%) developed
tumours, and none survived to the end of the trial, again exhibiting ancillary organ damage.
There is of course a big difference between mice and humans.
No one will debate the effectiveness of this drug in every test taken, as for management, well that's another story. Sokoll was just hired in Sep 2010 and is turning this ship around. We will file for IND in Q4 2011, or Q1 2012.